Roth Capital Partners upgraded Cempra (NASDAQ:CEMP) to “buy” and maintained its $8 price target after the company announced positive Phase 3 results in the first of two skin infection (ABSSSI) studies with Taksta. The stock was quoted at $4.20 near midday on Feb. 27.Read More
ARIAD Pharmaceuticals (NASDAQ:ARIA) has initiated a Phase 1/2 clinical trial of AP32788, an investigational tyrosine kinase inhibitor (TKI) designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in EGFR or HER2.
AP32788 targets tumors driven by EGFR or HER2 kinases and was designed to achieve selective inhibition of these kinases with exon 20 mutations. There are currently no approved targeted treatment options available for the approximately 4% to 9% of EGFR-mutated lung tumors with exon 20 insertion mutations in NSCLC patients.Read More
Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor cancers.
The primary goal of the study was to assess safety and tolerability of SOR-C13 in subjects with advanced carcinomas commonly known to express the TRPV6 channel and who had failed all previous anti-cancer treatments. SOR-C13 is the first drug candidate targeting TRPV6 to enter human clinical trials.Read More